Clinical Data GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints BioSpaceOver the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) BioSpace Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Norgine gets first EU approval for WHIM syndrome therapyNext: AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
